A
Avenzo Therapeutics
Developing the next generation of oncology therapies for patients
About Avenzo Therapeutics
Avenzo Therapeutics is a clinical-stage biotechnology company specializing in the development of next-generation oncology therapies. The company's primary focus is on treating solid tumors, with a pipeline that includes promising drug candidates for various types of cancer.
Read full description
Their lead asset, AVZO-021, is a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor. This drug is currently undergoing clinical trials to evaluate its efficacy in treating advanced solid tumors, such as breast cancer, ovarian cancer, and other cancers with cyclin E1 amplification. The development of AVZO-021 is part of a global license agreement with DualityBio.
In addition to AVZO-021, Avenzo is also advancing AVZO-023, a novel CDK4 selective inhibitor. This candidate has received FDA clearance for an Investigational New Drug (IND) application and is being tested in a Phase I/II trial for patients with HR+/HER2- metastatic breast cancer and other solid tumors. The company's business model revolves around identifying and licensing promising oncology assets and advancing them through clinical development. Avenzo has successfully raised significant capital through Series A and A-1 financing rounds, enabling it to fund its pipeline and research activities.
At a glance
- Status
- Operational
- Founded
- 2022
- Headquarters
- San Diego, United States
- Employees
- 60
- Open positions
- 11
- Dealroom signal
- 80.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Rumoured $1B, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Avenzo Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT VCOther financing | Jun 2026 | $215M | — | SR One · Longwood Fund · Foresite Capital · OrbiMed | ↗ |
| SERIES BOther financing | Sep 2025 | $60M | $240M | Longwood Fund · Foresite Capital · Delos Capital · SR One | ↗ |
Growth signals
Latest recorded traffic for Avenzo Therapeutics is 6.9K monthly website visits, up 9.5% over the last three months. Avenzo Therapeutics's team grew 3.4% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A14 investors entered at this stage
TF Capital
Quan Capital
INCE Capital
Deep Track Capital
NEA
Delos Capital
Sofinnova Investments
Sands Capital Management
Foresite Capital
Lilly Asia Ventures
SR One
OrbiMed
Surveyor Capital
Longwood Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Avenzo Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Avenzo Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.